推进非裔美国多发性硬化症患者的诊疗与结局
本文为叙述性综述,指出非裔美国多发性硬化症(MS)患者历史上存在诊断不足与治疗不足,近期证据显示其临床表现不同、疾病发病率与负担更高、长期结局较白人患者更差。临床试验中非裔美国人数据有限,难以对该人群的自然史、预后和治疗反应做出可靠推断。文章介绍了新近建立的美国非裔多发性硬化症登记处的使命与目标。
要点
- 非裔美国MS患者历史上存在诊断不足和治疗不足。
- 近期证据显示非裔美国MS患者临床表现不同、疾病发病率与负担更高、长期结局较白人患者更差。
- MS临床试验中非裔美国人数据有限,难以对该人群自然史、预后和治疗反应做出可靠推断。
核心结论
- 非裔美国MS患者存在健康差异,亟需增加对该群体MS疾病表现的认知与理解。
- 新建立的美国非裔多发性硬化症登记处旨在推进非裔美国MS患者的诊疗并应对其可能经历的健康差异。
研究设计与样本
- 叙述性综述,未报告系统检索范围与样本量。
主要发现
- 近期证据提示非裔美国MS患者临床表现不同、疾病发病率与负担更高、长期结局较白人患者更差。
- MS临床试验中非裔美国人数据有限,难以对该人群自然史、预后和治疗反应做出可靠推断。
局限性
- MS临床试验中非裔美国人数据有限,难以对该人群自然史、预后和治疗反应做出可靠推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS have a different clinical presentation, increased disease incidence and burden, and worse long-term outcomes vs their White counterparts. Due to limited data available for African Americans in MS clinical trials, it is difficult to make informed, generalizable conclusions about the natural history, prognosis, and therapeutic response in this population. In this narrative review, we highlight the nature and magnitude of the health disparities experienced by African Americans with MS and underscore the pressing need to increase knowledge about and understanding of MS disease manifestations in this group. In addition, we describe the mission and objectives of the recently established National African Americans with Multiple Sclerosis Registry, which is intended to be a platform to advance the care of African Americans with MS and address health disparities they may experience.
引用
- Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022. PMID: 35470139. doi:10.1212/WNL.0000000000200791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。